Terms: = Leukemia AND DDIT3, CHOP, 1649, ENSG00000175197, _C/EBP zeta_, MGC4154, GADD153, CHOP10, P35638
607 results:
1. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
3. [Synergistic effect of azacitidine with homoharringtonine by activating the c-MYC/ddit3/PUMA axis in acute myeloid leukemia].
Li J; Huang YQ; Zi J; Song CH; Ge Z
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1001-1009. PubMed ID: 38503523
[No Abstract] [Full Text] [Related]
4. C/ebpα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating ddit3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract] [Full Text] [Related]
5. A case of peripheral T-cell lymphoma in which therapy-related myelodysplastic syndrome developed and a second autologous transplantation was performed.
Nakagawa SI; Nukii Y; Mochizuki K; Uchiyama A; Maeda Y; Kurokawa T
J Clin Exp Hematop; 2024 Mar; 64(1):59-64. PubMed ID: 38417872
[TBL] [Abstract] [Full Text] [Related]
6. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract] [Full Text] [Related]
7. Epigenetic Modulation of ddit3 and MGMT Expression Acts Synergistically with Resistance to Imatinib towards CML Disease Progression: A Hospital based Study.
Hazarika G; Kalita MJ; Kalita S; Das PP; Dutta K; Lahkar L; Rajkonwar A; Idris MG; Khamo V; Kusre G; Medhi S
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4059-4069. PubMed ID: 38156838
[TBL] [Abstract] [Full Text] [Related]
8. Renomegaly and acute kidney injury as primary manifestations of non-Hodgkin's lymphoma: a report of three cases.
Bai Y; Zheng Y; Zhang Q; Jiang Q; Diao Z; Guo W; Liu S; Liu W
Diagn Pathol; 2023 Dec; 18(1):133. PubMed ID: 38066507
[TBL] [Abstract] [Full Text] [Related]
9. Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment.
Häselbarth L; Gamali S; Saul D; Krumbholz M; Böttcher-Loschinski R; Böttcher M; Zou D; Metzler M; Karow A; Mougiakakos D
BMC Cancer; 2023 Nov; 23(1):1153. PubMed ID: 38012567
[TBL] [Abstract] [Full Text] [Related]
10. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas.
Burton JS; Foley NC; Mehta-Shah N
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):65-76. PubMed ID: 37973458
[TBL] [Abstract] [Full Text] [Related]
11. [Adult T-cell leukemia/lymphoma].
Yoshimitsu M
Rinsho Ketsueki; 2023; 64(9):1032-1040. PubMed ID: 37899180
[TBL] [Abstract] [Full Text] [Related]
12. Poor Outcome of Adult T-Cell leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers.
Saeed H; Sandoval-Sus J; Castillo-Tokumori F; Dong N; Pullukkara JJ; Boisclair S; Brahim A; Walker D; Bridgellal S; Zhang L; Sokol L
Oncol Res Treat; 2023; 46(11):459-465. PubMed ID: 37844559
[TBL] [Abstract] [Full Text] [Related]
13. Mosunetuzumab in combination with chop in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
Olszewski AJ; Phillips TJ; Hoffmann MS; Armand P; Kim TM; Yoon DH; Mehta A; Greil R; Westin J; Lossos IS; Munoz JL; Sit J; Wei MC; Yang A; Chen V; Purev E; Yee DL; Jaeger U
Blood Adv; 2023 Oct; 7(20):6055-6065. PubMed ID: 37581593
[TBL] [Abstract] [Full Text] [Related]
14. Investigating the synergistic potential of TRAIL and SAHA in inducing apoptosis in MOLT-4 cancer cells.
Mohammad Mirzapour M; Farshdousti Hagh M; Marofi F; Solali S; Alaei A
Biochem Biophys Res Commun; 2023 Oct; 676():13-20. PubMed ID: 37480688
[TBL] [Abstract] [Full Text] [Related]
15. Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-chop pathway.
Hua L; Yang N; Li Y; Huang K; Jiang X; Liu F; Yu Z; Chen J; Lai J; Du J; Zeng H
Br J Haematol; 2023 Sep; 202(5):971-984. PubMed ID: 37409755
[TBL] [Abstract] [Full Text] [Related]
16. The clinical impact of the ratio of C-reactive protein to albumin (CAR) in patients with acute- and lymphoma-type adult T-cell leukemia-lymphoma (ATL).
Kawano N; Shimonodan H; Nagahiro Y; Yoshida S; Kuriyama T; Takigawa K; Tochigi T; Nakaike T; Makino S; Yamashita K; Marutsuka K; Ochiai H; Mori Y; Shimoda K; Ohshima K; Mashiba K; Kikuchi I
J Clin Exp Hematop; 2023; 63(2):73-82. PubMed ID: 37380472
[TBL] [Abstract] [Full Text] [Related]
17. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
Roh J; Pak HK; Jeong S; Hwang S; Kim DE; Choi HS; Kim SJ; Kim H; Cho H; Park JS; Jeong SH; Choi YS; Han JH; Yoon DH; Park CS
Biochem Biophys Res Commun; 2023 Sep; 673():36-43. PubMed ID: 37356143
[TBL] [Abstract] [Full Text] [Related]
18. Loss of the mitochondrial protein Abcb10 results in altered arginine metabolism in MEL and K562 cells and nutrient stress signaling through ATF4.
Miljkovic M; Seguin A; Jia X; Cox JE; Catrow JL; Bergonia H; Phillips JD; Stephens WZ; Ward DM
J Biol Chem; 2023 Jul; 299(7):104877. PubMed ID: 37269954
[TBL] [Abstract] [Full Text] [Related]
19. Melatonin Can Enhance the Effect of Drugs Used in the Treatment of leukemia.
Lomovsky AI; Baburina YL; Fadeev RS; Lomovskaya YV; Kobyakova MI; Krestinin RR; Sotnikova LD; Krestinina OV
Biochemistry (Mosc); 2023 Jan; 88(1):73-85. PubMed ID: 37068876
[TBL] [Abstract] [Full Text] [Related]
20. Immune priming with avelumab and rituximab prior to R-chop in diffuse large B-cell lymphoma: the phase II AvR-chop study.
Manos K; Chong G; Keane C; Lee ST; Smith C; Churilov L; McKendrick J; Renwick W; Blombery P; Burgess M; Nelson NE; Fancourt T; Hawking J; Lin W; Scott AM; Barraclough A; Wight J; Grigg A; Fong CY; Hawkes EA
Leukemia; 2023 May; 37(5):1092-1102. PubMed ID: 36906715
[TBL] [Abstract] [Full Text] [Related]
[Next]
